Jefferies Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Maury Raycroft initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and a price target of $6.

March 13, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has initiated coverage on Cue Biopharma with a Buy rating and set a price target of $6.
The initiation of coverage by a reputable analyst firm like Jefferies, especially with a Buy rating and a specific price target, typically generates positive sentiment among investors. This can lead to increased investor interest and potentially drive the stock price up in the short term, as the market reacts to the new coverage and price target.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100